预测高危原发性或复发性前列腺癌中18F-DCFPyL PSMA PET/CT不确定骨病变的结局
研究纳入243例高危原发性或生化复发前列腺癌患者的18F-DCFPyL PET/CT,其中48例(19.8%)共98个不确定骨病变(IBL)。多因素分析显示高SUVmax(OR 13.87,P=0.0089)或合并其他骨转移(OR 11.35,P=0.003)预测恶性。结论认为结合位置、SUV及伴随骨转移特征可辅助判读。
要点
- 243例中48例(19.8%)发现98个不确定骨病变,42个判为恶性,37个判为良性。
- 多因素分析:高SUVmax预测恶性OR 13.87(P=0.0089),合并其他骨转移OR 11.35(P=0.003)。
- SUVmax≥5或合并其他骨转移倾向恶性;SUVmax<5且仅见于不典型位置倾向良性。
核心结论
- PSMA PET/CT上的不确定骨病变值得关注,但结合位置、SUV及额外扫描所见可辅助判读。
- SUVmax至少5或合并其他骨转移的IBL倾向恶性。
- 无伴随骨转移、SUVmax小于5且仅见于不典型位置的IBL倾向良性。
- 这些判读要点可能有助于PSMA PET/CT上IBL的解读。
研究设计与样本
- 对243例高危原发性或生化复发前列腺癌患者行18F-DCFPyL PET/CT显像。
- 回顾病历确定每个IBL的最终性质:随访进展或活检证实为恶性,随访稳定为良性,证据不足为不确定。
- 采用Wilcoxon秩和检验与χ2检验分析患者、病变及扫描变量,并用logistic回归评估预测因素。
主要发现
- 243例中48例(19.8%)共检出98个IBL,占267个骨病变的36.7%。
- 98个IBL中37个判为良性、42个判为恶性(其中8个经组织学验证)、19个仍不确定。
- 病变位置与SUVmax分类变量可预测IBL判读(P=0.0201与P=0.0230)。
- 新判读的IBL中,判为良性的37个里有34个(91.9%)SUVmax小于5或为局灶摄取且无共存骨转移;判为恶性的42个里有37个(88.1%)SUVmax至少5或合并共存骨转移。
- Logistic回归显示高SUVmax(单变量OR 9.29,P=0.0016;多变量OR 13.87,P=0.0089)或合并其他骨转移(单变量OR 9.87,P=0.0112;多变量OR 11.35,P=0.003)预测恶性。
关键数值与推荐
- SUVmax至少5或合并其他骨转移的IBL倾向恶性。
- 无伴随骨转移、SUVmax小于5且仅见于不典型位置的IBL倾向良性。
- 病变位置(P=0.0201)与SUVmax分类(P=0.0230)为IBL判读的预测变量。
临床怎么用
- 原文结论认为这些判读要点可能有助于PSMA PET/CT上IBL的解读。
局限性
- 98个IBL中19个因证据不足或不清仍为不确定。
- 42个判为恶性的IBL中仅8个经组织学验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Indeterminate bone lesions (IBLs) on prostate-specific membrane antigen (PSMA) PET/CT are common. This study aimed to define variables that predict whether such lesions are likely malignant or benign using features on PSMA PET/CT. Methods: 18F-DCFPyL PET/CT imaging was performed on 243 consecutive patients with high-risk primary or biochemically recurrent prostate cancer. IBLs identified on PSMA PET/CT could not definitively be interpreted as benign or malignant. Medical records of patients with IBLs were reviewed to determine the ultimate status of each lesion. IBLs were deemed malignant or benign on the basis of evidence of progression or stability at follow-up, respectively, or by biopsy results; IBLs were deemed equivocal when insufficient or unclear evidence existed. Post hoc patient, lesion, and scan variables accounting for clustered data were evaluated using Wilcoxon rank-sum and χ2 tests to determine features that favored benign or malignant interpretation. Results: Overall, 98 IBLs within 267 bone lesions (36.7%) were identified in 48 of 243 patients (19.8%). Thirty-seven of 98 IBLs were deemed benign, and 42 were deemed malignant, of which 8 had histologic verification; 19 remained equivocal. Location and SUVmax categorical variables were predictive of IBL interpretation (P = 0.0201 and P = 0.0230, respectively). For IBLs with new interpretations, 34 of 37 (91.9%) considered benign showed an SUVmax of less than 5 or exhibited focal uptake without coexisting bone metastases; 37 of 42 (88.1%) deemed malignant demonstrated an SUVmax of at least 5 or were present with coexisting bone metastases. Logistic regression predicted IBLs with a high SUVmax (univariable: odds ratio [OR], 9.29 [P = 0.0016]; multivariable: OR, 13.87 [P = 0.0089]) or present with other bone metastases (univariable: OR, 9.87 [P = 0.0112]; multivariable: OR, 11.35 [P = 0.003]) to be malignant. Conclusion: IBLs on PSMA PET/CT are concerning; however, characterizing their location, SUV, and additional scan findings can aid interpretation. IBLs displaying an SUVmax of at least 5 or present with other bone metastases favor malignancy. IBLs without accompanying bone metastases that exhibit an SUVmax of less than 5 and are observed only in atypical locations favor benign processes. These guidelines may assist in the interpretation of IBLs on PSMA PET/CT.
引用
- Phelps TE, Harmon SA, Mena E, et al. Predicting Outcomes of Indeterminate Bone Lesions on 18F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer. J Nucl Med. 2022. PMID: 36265908. doi:10.2967/jnumed.122.264334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。